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Abstract
Objectives To assess the extent to which funding and study design are
associated with high reprint orders.
Design Case-control study.
Setting Top articles by size of reprint orders in seven journals, 2002-09.
Participants Lancet, Lancet Neurology, Lancet Oncology (Lancet
Group), BMJ, Gut, Heart, and Journal of Neurology, Neurosurgery &
Psychiatry (BMJ Group) matched to contemporaneous articles not in
the list of high reprint orders.
Main outcomemeasures Funding and design of randomised controlled
trials or other study designs.
Results Median reprint orders for the seven journals ranged from 3000
to 126 350. Papers with high reprint orders were more likely to be funded
by the pharmaceutical industry than were control papers (industry funding
versus other or none: odds ratio 8.64, 95% confidence interval 5.09 to
14.68, and mixed funding versus other or none: 3.72, 2.43 to 5.70).
Conclusions Funding by the pharmaceutical industry is associated with
high numbers of reprint orders.
Introduction
Reprints of published articles are a potential valuable means of
disseminating information.1Many individuals and organisations
may request reprints, including the authors of the articles
themselves, other members of the scientific community, study
sponsors, and pharmaceutical companies. The pharmaceutical
industry is thought to be the largest purchaser of reprints. After
gifts and drug samples, reprints are the most common form of
promotional material circulated among doctors by
pharmaceutical companies.2
Because pharmaceutical companies may buy from journals
copies of articles they have funded, reprints of published articles
have been suggested as a possible source of conflict of interest
that could lead to publication bias. Orders can be worth large
sums of money and could potentially influence the chance of a
paper being accepted, especially with the current organisational
framework, under which editors can be responsible for the
journal’s content and its finances.3 Studies sponsored by the
pharmaceutical industry are also more likely to be published in
higher impact factor journals than are studies without industry
funding.4
Data on the numbers of reprints ordered are scarce. One study
examined the characteristics of articles published in the Lancet
in 1998 in the top 21 of reprint orders and compared these with
a set of control articles from the same journal.5 Reprint orders
were not reported in detail, but less than 25% were stated to
concern over 100 000 copies. Studies sponsored by the
pharmaceutical industry were marginally significantly
over-represented in the high reprint group compared with the
control articles. Using more recent data we report the number
of reprints ordered for the top articles by reprint order in medical
journals, identify the sponsors and designs of these studies, and
quantify the possible financial implications for journals.
Methods
We emailed the editors in chief of the Journal of the American
Medical Association, Lancet,NewEngland Journal ofMedicine,
Correspondence to: S V Ramagopalan s.ramagopalan@qmul.ac.uk
Extra material supplied by the author (see http://www.bmj.com/content/344/bmj.e4212?tab=related#webextra)
Full data for high reprint and control articles
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Annals of Internal Medicine, and BMJ to supply details of the
top articles by size of reprint orders (the high reprint group).
For each journal we selected control articles immediately before
the high reprint article from the same section of the same issue
or, where this was not possible, the first article in the same
section of the previous issue. The control article was always of
the same type as the high reprint article (research article,
editorial, etc) and could not be in the high reprint group. We
discarded reprint orders for articles when suitable controls could
not be found or financial disclosures were lacking. Several
articles appeared multiple times in the top reprint groups of
successive years; we counted these articles only once but
summed the reprint orders. Table 1⇓ shows the total numbers
of high reprint and control articles for each journal.
Study design and source of funding
Each study was categorised as either a randomised control trial
or another study design (including meta-analysis, observational
study, basic science, and commentary). We extracted the source
of funding from the acknowledgments or conflicts of interest
section and classified this into industry funding, mixed funding,
or other sources of funding. Research articles were classified
as being industry funded if all of the funding for the study was
supplied by a pharmaceutical company, and mixed if some of
the funding was supplied by a pharmaceutical company. Other
article types, such as commentaries, were classified as being
industry funded if the body of the article referred to a
pharmaceutical product and the author or authors received
funding, honorariums, or salaries from the pharmaceutical
company related to that product. Two authors (AEH and JP)
independently appraised the funding status of all articles and
compared results. Discrepancies were resolved by consensus
with a third author (SVR).
The costs for the reprint orders were obtained directly from the
BMJ and Lancet on 15 August 2011.
Statistical analysis
We used logistic regression to calculate odds ratios and 95%
confidence intervals for comparisons between the high reprint
and control groups, using study design and funding as
explanatory variables. The data were analysed as clustered data,
with journal and issue as the cluster unit. Using the random
effects model we calculated the I2 value to assess heterogeneity
between the journals. We considered P values <0.05 as
significant. Statistical analyses were done in Stata 12.0.0.
Results
Journal responses
Only the Lancet Group and BMJGroup responded to the request
for data, providing the top 20 reprint articles each year for the
Lancet and BMJ, top 10 reprint articles each year for Heart,
Gut, and the Journal of Neurology, Neurosurgery & Psychiatry,
and the top five reprint articles each year for Lancet Neurology
and Lancet Oncology.
Lancet initially provided data from 2002 to 2009, and thus for
consistency data were requested for this period from the other
journals and used in all analyses.
Reprint orders
Table 1 shows the average reprint orders for the top reprinted
articles by journal. Lancet had by far the highest median number
of reprints, with a median order of 126 350 for its high reprint
group (range 24 000-835 100). The BMJ and Lancet Oncology
had median reprint orders greater than 10 000 (13 248 and 10
500, respectively), whereas the other journals hadmedian reprint
orders of 5200 or less. Notably, 62.3% of reprint orders in
Lancet were in excess of 100 000 copies, higher than the 24%
found by other researchers.5 Table 2⇓ gives the proportion of
all reprint orders in excess of 100 000 copies.
Funding and study design
Table 3⇓ summarises the characteristics of the articles in the
high reprint and control groups. (See the supplementary file for
a full list of the case and control articles, along with their
categorisation according to funding.) The inter-rater agreement
for categorisation by funding and study design was excellent
(κ=0.97). When all journal data were pooled, high reprint order
papers were more likely to be funded by the pharmaceutical
industry than control papers: industry funding versus other or
none, odds ratio 8.64 (95% confidence interval 5.09 to 14.38);
mixed funding versus other or none, 3.72 (2.43 to 5.70). Articles
with high reprint orders were no more likely to be randomised
controlled trials than other study designs (1.04, 0.70 to 1.54).
Considering each journal individually, papers with high reprint
orders were significantly more likely to be funded by industry
in all journals except Gut, where the trend was for high reprint
papers to be funded by industry. The effect of industry funding
on being a high reprint paper was similar across all studies
(I2=0%, P=0.74), as was the effect of mixed funding (I2=0%,
P=0.70).Gutwas the only journal where randomised controlled
trials were significantly more likely to have high reprint orders,
with Heart trending towards a similar association. The effect
of study design was similar across all journals (I2=16.9%,
P=0.30).
Financial implications
Table 4⇓ presents the cost for the median and largest reprint
order for each journal. This ranged from £4002 (€4962; $6276)
(Gut) to £1 551 794 (Lancet).
Discussion
High reprint articles, irrespective of journal, were significantly
more likely to be sponsored by the pharmaceutical industry.
General medical journals hadmore reprint orders than speciality
journals. Some of the reprint orders were substantial, equating
to a large amount of income generated. Thus reprint orders could
potentially be a source of publication bias, although our study
was not designed with this in mind. An overall association of
study design with reprint orders was not apparent, although this
might differ by journal.
Limitations of the study
The key limitation of our study was the scope of the data. Firstly,
we were only able to obtain data from one general medical
journal that does not use open access publishing (the BMJ
publishes all research journals as open access), as our requests
for data were declined by other journals approached. The editor
in chief of the Journal of the American Medical Association
explained that the information requested was proprietary and
would not be released to anyone. The managing director of
publishing at the New England Journal of Medicine explained
that its business practice precluded sharing data on reprint
orders. The vice president of publishing for the Annals of
Internal Medicine stated that it would require too much work
to compile the data. For the Journal of the American Medical
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Association, New England Journal of Medicine, and Annals of
Internal Medicine we were told that the editor in chief does not
have involvement in specific data on reprint orders. It is
unknown how representative the Lancet and BMJ are of other
medical journals.
Secondly, we analysed data only for the top 5-20 most highly
ordered papers. It is possible that the excess of industry funded
studies is less pronounced or even reversed outside the most
highly reprinted papers. The impact of such a difference would
depend on how the overall income from the “long tail” of a large
number of studies with lower reprint orders compares with the
income from these high reprint papers. Addressing such a
question would require a cohort study of reprint orders for all
papers published by a journal: this would be a far larger project
than this case-control study and would require access to an even
larger quantity of commercial data from journals.
Background from other studies
We are aware of one study dealing with this specific research
question, which examined the characteristics of articles
published in the Lancet during 1998 and focused primarily on
analysing citation patterns.5 That study reported a larger
over-representation of industry sponsored studies in the high
reprint group compared with the control group (12/21 v 5/21
odds ratio 4.27, 95% confidence interval 1.13 to 16.05, P=0.03).
This is lower than we observed—the high reprint articles in the
Lancet and all journals combined were, respectively, 12 and
eight more times likely to be funded by a pharmaceutical
company.
Conclusions and policy implications
We have identified a potential source of publication bias among
several medical journals. This will need confirmation from data
generated by other publication groups and further research. We
emphasise that there is currently no evidence that the potential
for future reprint orders influences decisions to publish particular
articles. This is especially true given that reprint orders are only
realised after the publication of studies. Moreover, the patterns
of reprint orders may be changing substantially over time (for
example, an increase in their use as teaching material), which
may obscure any potential bias. However, because reprints
provide considerable sources of revenue, we would suggest that
data on reprint orders should be made more available generally
and that specific data for reprint orders should be included with
individual articles.
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What is already known on this topic
Reprint orders have been suggested as a possible source of publication bias
Articles sponsored by the pharmaceutical industry are more likely to report favourable results than studies sponsored by other funding
sources
One small study suggested an over-representation of industry sponsored studies in the top 21 reprint orders in Lancet
What this study adds
In all seven journals studied, industry sponsored articles were significantly over-represented among those most frequently requested
as reprints
Reprint orders represent a large source of income for the Lancet and BMJ
Tables
Table 1| Included articles and average reprint orders by journal study design and funding
Median reprints
and range*
Control articlesHigh reprint articles
Journal
Other or
none
Mixed
funding
Industry
funding
Other
designRCTNo
Other or
none
Mixed
funding
Industry
funding
Other
designRCTNo
126 350 (24
000-835 100)
52132339498881763147488Lancet
5200 (200-50 000)19512232589817825Lancet
Neurology
10 500 (500-63
500)
21321972611411161026Lancet
Oncology
13 248 (1000-526
650)
60102591372431910531972BMJ
3000 (1000-322
000)
376341546161218242246Gut
3000 (1000-350
000)
12233233516712241135Heart
4008 (1000-107
110)
415043346141715291746Journal of
Neurology,
Neurosurgery
& Psychiatry
13 495 (200-835
100)
320136256833392583645178161339Combined
journals
RCT=randomised controlled trial.
Numbers quoted discount multiple reprint orders placed on same articles.
*Median number of reprints and range include all reprint orders regardless of article duplication.
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Table 2| Percentage of all high reprint order articles with total reprints in excess of 100 000 copies by journal
>100 000 reprints (% of articles with >100 000 reprints)
No of articlesJournal Other or noneMixed fundingIndustry fundingOverall
6 (10.9)10 (18.2)39 (70.9)55 (62.5)88Lancet
0 ()0 (0)0 (0)0 (0)25Lancet Neurology
0 (0)0 (0)1 (100)1 (3.8)26Lancet Oncology
5 (50)4 (40)1 (10)10 (13.9)72BMJ
003 (100)3 (6.5)46Gut
001 (100)1 (2.9)35Heart
01 (50)1 (50)2 (4.3)46Journal of Neurology, Neurosurgery & Psychiatry
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Table 3| Multiple logistic regression analysis showing odds ratios of articles being in high reprint versus control groups by design and
funding
P value
Mixed funding v other or noneIndustry funding v other or noneRCT v other design
Journal Odds ratio (95% CI)Odds ratio (95% CI)P valueOdds ratio (95% CI)
<0.0015.13 (1.75 to 15.04)12.43 (4.63 to 33.38)0.621.27 (0.50 to 3.23)Lancet
0.034.06 (0.96 to 17.12)15.73 (0.93 to 264.88)0.890.87 (0.11 to 7.12)Lancet Neurology
0.0032.64 (0.56 to 12.37)27.36 (2.43 to 307.97)0.460.55 (0.11 to 2.64)Lancet Oncology
0.0012.76 (1.16 to 6.60)15.64 (1.75 to 139.48)0.780.88 (0.35 to 2.21)BMJ
0.072.54 (0.83 to 7.78)4.31 (1.02 to 18.25)0.0453.70 (1.03 to 13.31)Gut
0.024.79 (1.07 to 21.41)6.00 (1.08 to 33.33)0.0525.38 (0.98 to 29.36)Heart
<0.00110.15 (2.79 to 36.88)NA0.311.32 (0.23 to 7.69)Journal of Neurology, Neurosurgery &
Psychiatry
<0.0013.72 (2.43 to 5.70)8.64 (5.09 to 14.68)0.851.04 (0.70 to 1.54)Combined journals
—0.0 (0.74)0.0 (0.70)16.9 (0.30)I2 (%) (P value)
RCT=randomised controlled trial; NA=not applicable.
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Table 4| Median and maximum costs for reprint orders
Reprint order cost (£)
Journal MaximumMedian
132 80512 458BMJ
132 8057624Journal of Neurology, Neurology & Psychiatry
260 0554002Gut
334 2406071Heart
1 551 794287 353Lancet
87 24414 336Lancet Neurology
104 85724 390Lancet Oncology
£1.00 (€1.24; $1.57).
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